MDNA Fundamental Analysis - MEDICENNA THERAPEUTICS CORP

Fundamental Rating

Taking everything into account, MDNA scores 2 out of 10 in our fundamental rating. MDNA was compared to 24 industry peers in the Biotechnology industry. The financial health of MDNA is average, but there are quite some concerns on its profitability. MDNA has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

MDNA had negative earnings in the past year.

In the past year MDNA has reported a negative cash flow from operations.

In the past 5 years MDNA always reported negative net income.

In the past 5 years MDNA always reported negative operating cash flow.

1.2 Ratios

MDNA's Return On Assets of -57.51% is fine compared to the rest of the industry. MDNA outperforms 62.50% of its industry peers.

With a decent Return On Equity value of -89.45%, MDNA is doing good in the industry, outperforming 79.17% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-57.51%
ROE	-89.45%
ROIC	N/A

ROA(3y)-67.42%

ROA(5y)-67.89%

ROE(3y)-195.49%

ROE(5y)-148.03%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MDNA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MDNA has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, MDNA has more shares outstanding

Compared to 1 year ago, MDNA has a worse debt to assets ratio.

2.2 Solvency

MDNA has an Altman-Z score of -3.08. This is a bad value and indicates that MDNA is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -3.08, MDNA is in the better half of the industry, outperforming 70.83% of the companies in the same industry.

A Debt/Equity ratio of 0.01 indicates that MDNA is not too dependend on debt financing.

The Debt to Equity ratio of MDNA (0.01) is better than 79.17% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	-3.08

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 4.94 indicates that MDNA has no problem at all paying its short term obligations.

MDNA has a better Current ratio (4.94) than 79.17% of its industry peers.

A Quick Ratio of 4.94 indicates that MDNA has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 4.94, MDNA is in the better half of the industry, outperforming 79.17% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.94
Quick Ratio	4.94

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MDNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.76%, which is quite impressive.

EPS 1Y (TTM)56.76%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-20%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 0.46% on average over the next years.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-66.6%

EPS Next 2Y-26.41%

EPS Next 3Y0.46%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MDNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year MDNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-26.41%

EPS Next 3Y0.46%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MDNA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEDICENNA THERAPEUTICS CORP

TSX:MDNA (8/29/2025, 7:00:00 PM)

1.09

+0.04 (+3.81%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)07-31 2025-07-31/amc

Earnings (Next)11-12 2025-11-12

Inst Owners6.32%

Inst Owner ChangeN/A

Ins Owners14.2%

Ins Owner ChangeN/A

Market Cap90.92M

Analysts82.5

Price Target3.67 (236.7%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)57.52%

Min EPS beat(2)-17.65%

Max EPS beat(2)132.68%

EPS beat(4)2

Avg EPS beat(4)32.6%

Min EPS beat(4)-17.65%

Max EPS beat(4)132.68%

EPS beat(8)5

Avg EPS beat(8)-9.59%

EPS beat(12)9

Avg EPS beat(12)9.13%

EPS beat(16)12

Avg EPS beat(16)10.73%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-10.25%

PT rev (3m)-10.25%

EPS NQ rev (1m)-8.33%

EPS NQ rev (3m)18.75%

EPS NY rev (1m)11.45%

EPS NY rev (3m)11.45%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	6.21
P/tB	6.23
EV/EBITDA	N/A

EPS(TTM)-0.16

EYN/A

EPS(NY)-0.24

Fwd EYN/A

FCF(TTM)-0.21

FCFYN/A

OCF(TTM)-0.21

OCFYN/A

SpS0

BVpS0.18

TBVpS0.17

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-57.51%
ROE	-89.45%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-67.42%

ROA(5y)-67.89%

ROE(3y)-195.49%

ROE(5y)-148.03%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	2.99%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.94
Quick Ratio	4.94
Altman-Z	-3.08

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)56.76%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-20%

EPS Next Y-66.6%

EPS Next 2Y-26.41%

EPS Next 3Y0.46%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-19.81%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-28.16%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-28.15%

OCF growth 3YN/A

OCF growth 5YN/A

MEDICENNA THERAPEUTICS CORP (MDNA.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens